Actively Recruiting
Determination of Lipocalin Type-prostaglandin (L-PGDS) in Blood, Urine, Vaginal Samples and Endometrial Ablation by Enzyme-linked Immunosorbent Assay
Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2026-03-18
60
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prostaglandin D2 (PGD2) has anti-inflammatory activity, particularly via Lipocalin type-prostaglandin (L-PGDS). L-PGDS has been studied in pathologies such as sleep apnea, rheumatoid arthritis, asthma and allergic phenomena, but never in adenomyosis. Adenomyosis is a estrogen-dependent multifactorial pathology whose pathophysiology is still poorly defined. This hyperestrogenism causes chronic inflammation, particularly via the activation of the prostaglandin H2 (PGH2) signaling pathway. This would lead to the excess production of prostaglandins E2 (PGE2) and F2a (PGF2a) and the decrease of PGD2 and therefore of L-PGDS, leading to the proliferation of endometrial cells in the myometrium by the epithelial-mesenchymal transition via aromatase. A preliminary study comparing the expression of L-PGDS found a significant decrease in L-PGDS in the uterus of women with adenomyosis lesions versus healthy controls. However, during this study, some information was not collected, including the patients' symptoms, preoperative radiological data and surgical indication. The study authors hypothesize that L-PGDS could be a potential tissue and circulating diagnostic marker of adenomyosis in its early stages. L-PGDS appears to be a good candidate to aid in the diagnosis of adenomyosis via a minimally invasive assay for patients (blood or urine).
CONDITIONS
Official Title
Determination of Lipocalin Type-prostaglandin (L-PGDS) in Blood, Urine, Vaginal Samples and Endometrial Ablation by Enzyme-linked Immunosorbent Assay
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient has given free and informed consent and signed the consent form
- Patient is a member or beneficiary of a health insurance plan
- Female participants
- For adenomyosis groups: aged 28 to 57 years, non-menopausal, indication for total inter-ovarian hysterectomy for non-oncologic reasons, diagnosed with adenomyosis or other functional uterine pathology
- For control group: aged 18 to 57 years, asymptomatic with no menometrorrhagia or pelvic pain, undergoing medically assisted procreation evaluation, no uterine pathology on endovaginal ultrasound
You will not qualify if you...
- History of autoinflammatory or autoimmune disease
- History of atopic or asthmatic conditions
- History of sleep apnea syndrome
- Chronic or acute renal failure
- Liver failure
- History of active cancer or neoplasia
- Use of NSAIDs, corticosteroids, or aspirin within 15 days before L-PGDS measurement
- Use of estrogen-progestin hormonal contraception
- Contraindication to MRI for adenomyosis groups
- Refusal of endovaginal ultrasound for control group
- Presence of functional ovarian cyst on imaging for control group
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Nimes
Nîmes, France, 30029
Actively Recruiting
Research Team
S
Stéphanie HUBERLANT
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here